Drug profile

The FDA adverse-event record for Sulfamethoxazole/Trimethoprim

Name: Sulfamethoxazole/Trimethoprim - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

14 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Sulfamethoxazole/Trimethoprim. See the species affected, top reactions, and outcomes below.

14
adverse-event reports: 0.0%
death-coded share: Dog
most-reported species: 3
Skin lesion NOS - top reaction

Compiled by PlainBreed Editorial, Pet Health Editorial Team

Verify with FDA CVM →

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

0.0%

Death Rate

Active Ingredients

Sulfamethoxazole/Trimethoprim

Administration Routes

OralUnknown

Species Affected

Dog 11

Human 1

Cat 1

Horse 1

Most Affected Breeds

Unknown 2

Pit Bull 2

Retriever - Labrador 2

Beagle 1

Cat (unknown) 1

Dog (unknown) 1

Horse (unknown) 1

Spaniel - Springer English 1

Crossbred Canine/dog 1

Terrier - Bull 1

Most Reported Reactions

Skin lesion NOS 3

Lethargy (see also Central nervous system depression in 'Neurological') 3

Shaking 2

Pustules 2

Cellulitis 2

Injection site swelling 2

Musculoskeletal disorder NOS 2

Other abnormal test result NOS 2

Weight loss 2

Vomiting 2

Urinary incontinence 2

Diarrhoea 2

Outcome Breakdown

Ongoing

6 (42.9%)

Outcome Unknown

5 (35.7%)

Recovered/Normal

2 (14.3%)

Recovered with Sequela

1 (7.1%)

Sulfamethoxazole/Trimethoprim Adverse Event Insights

14 reports name Sulfamethoxazole/Trimethoprim; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Sulfamethoxazole/Trimethoprim. Administration routes: Oral, Unknown.

By species: Dog (11 reports), Human (1 reports), Cat (1 reports). By breed: Unknown (2), Pit Bull (2), Retriever - Labrador (2).

Leading clinical signs: Skin lesion NOS (3), Lethargy (see also Central nervous system depression in 'Neurological') (3), Shaking (2), Pustules (2). Outcome, 14 coded reports: Ongoing leads at 42.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.